| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer | Chief Corp. Dev. Officer
1 company
Shafique Virani last filed a Form 4 in January 2024, as Chief Business Officer at RXRX. From April 2021 to January 2024, the filings on record show 0 open-market purchases and 17 sales. Shafique Virani's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Shafique Virani a strong insider score of 70/100, based on 22 past trades. Over a 12-month horizon, 68.2% of those trades were profitable, with an average 12-month return of +13.2%.
At the last filing, the largest reported position was 136,748 shares of RXRX. The RXRX filings lean toward selling, a net 400,119 shares.
Shares as reported in the last Form 4 for each company; the most recent is from January 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 9,254 | $8.35 | $77,244.94 | -4.7% | -31.2% | +68.2% | |
| Jan 17, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 10,000 | $9.16 | $91,561.00 | -12.0% | -31.7% | +11.8% | |
| Dec 15, 2022 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 10,000 | $8.85 | $88,525.00 | -11.3% | -11.7% | +14.5% | |
| Nov 15, 2022 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 10,000 | $12.31 | $123,122.80 | -10.7% | -32.7% | -39.5% | |
| Oct 14, 2022 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 10,000 | $10.92 | $109,179.50 | -10.1% | -17.0% | -39.2% | |
| Sep 15, 2022 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 10,000 | $13.36 | $133,634.76 | -9.6% | -30.4% | -34.6% | |
| Aug 16, 2022 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 30,000 | $12.61 | $378,444.00 | -23.3% | +3.1% | -29.4% |